Experimental therapy of filovirus infections

Antiviral Research

Volumn 54, Issue 1, 2002, Pages 1-17

  Bray, Mike ^a   Paragas, Jason ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral therapy; Ebola virus; Filovirus; Interferon ; Marburg virus; S adenosyl L homocysteine hydrolase

Indexed keywords

3 DEAZAADENOSINE; 3 DEAZANEPLANOCIN A; ADENOSYLHOMOCYSTEINASE; ADENOSYLHOMOCYSTEINASE INHIBITOR; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; COMPLEMENTARY DNA; CYANOVIRIN N; DEFEROXAMINE MESYLATE; GLYCOPROTEIN; GLYCOPROTEIN ANTIBODY; GLYCYRRHIZIC ACID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; PROTEINASE; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIDOSTIN; RNA DIRECTED RNA POLYMERASE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VIRUS RECEPTOR; VIRUS RNA;

ANTIVIRAL ACTIVITY; BABOON; BLOOD TRANSFUSION; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EBOLA VIRUS; ENZYME INHIBITION; FILOVIRUS; GUINEA PIG; HUMAN; INFECTION PREVENTION; MACACA; MARBURG VIRUS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; TRANSCRIPTION REGULATION; VIRAL GENETICS; VIRION; VIROGENESIS; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HUMANS; RESEARCH; SYNDROME; VIRION; VIRUS REPLICATION;

CAVIA PORCELLUS; DNA VIRUSES; EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; MACACA; MARBURG-LIKE VIRUSES; PAPIO HAMADRYAS; RNA VIRUSES; SUS SCROFA;

EID: 0036125253     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00005-0     Document Type: Review

References (79)

1. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice
2. Chemistry and biochemistry of 2′,5′-oligoadenylate-based antisense strategy
3. Antiviral immunotoxins: Antibody-mediated delivery of gelonin inhibits Pichinde virus replication in vitro
4. The Ebola virus VP35 protein functions as a type I IFN antagonist
5. The asialoglyco protein receptor is a potential liver-specific receptor for Marburg virus
6. Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART
7. Development and study of the properties of immunoglobulin against Ebola fever
8. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development
9. The role of the Type I interferon response in the resistance of mice to filovirus infection
10. Filoviridae
11. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
12. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor
13. Haematological, biochemical, and coagulation changes in mice, guinea pigs, and monkeys infected with a mouse adapted variant of Ebola Zaire virus
14. 3-Deazaneplanocin A induces massively increased interferon-a production in Ebola virus-infected mice
15. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses
16. Developing methods of specific heterologic immunoglobulins preparation for urgent prevention of Ebola fever and study of their properties
17. Pathogenesis of experimental Ebola virus infection in guinea pigs
18. Influence of S-adenosylhomocysteine hydrolase inhibitors on S-adenosylhomocysteine and S-adenosylmethionine pool levels in L929 cells
19. S-adenosylhomocysteine hydrolase inhibitors as broad spectrum antiviral agents
20. Carbocyclic adenosine analogues as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: Recent advances
21. A case of Ebola virus infection
22. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages
23. Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses
24. Differentiation of filoviruses by electron microscopy
25. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses
26. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice
27. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro
28. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication
29. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells
30. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells
31. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: Implications for filovirus budding
32. Rhabdoviruses and the cellular ubiquitin-proteasome system: A budding interaction
33. Proinflammatory response during Ebola virus infection of primate models: Possible involvement of the tumor necrosis factor receptor superfamily
34. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug
35. Inhibition of Ebola virus replication in vitro and in a SCID mouse model by S-adenosylhomocysteine hydrolase inhibitors
36. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model
37. Experimental study of possible treatment of Marburg hemorrhagic fever with desferal, ribavirin, and homologous interferon
38. Experimental study on the possibility of treatment of some hemorrhagic fevers
39. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses
40. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections
41. Ebola virus VP40-induced particle formation and association with the lipid bilayer
42. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
43. Immune recognition of foreign DNA: A cure for bioterrorism?
44. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo
45. The isolation of hyperimmune horse serum to the Ebola virus
46. Preparation of hyperimmune horse serum against Ebola virus
47. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections
48. Developing principles for emergency prevention and treatment of Ebola fever
49. Recombinant human monoclonal antibodies to Ebola virus
50. Ebola virus can be effectively neutralized by antibody produced in natural human infection
51. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells
52. The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever
53. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems
54. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients
55. Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes
56. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture
57. A case of a laboratory infection with Marburg fever
58. Adenosine analogs inhibit the guanine-7-methylation of mRNA cap structures
59. In vivo testing of anti-HIV immunotoxins
60. Inhibition of Marburg virus reproduction by glycyrrhizinic acid and its derivatives
61. An update on respiratory syncytial virus antiviral agents
62. Monoclonal antibodies to Marburg virus proteins and their immunochemical characteristics
63. An analysis of features of pathogenesis in two animal models of Ebola virus infection
64. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: Determinants of survival
65. Filoviridae: Marburg and Ebola viruses
66. Viruses and interferons
67. Study of the treatment-prophylactic effect of immunomodulators in experimental infections, caused by Marburg, Ebola, and Venezuelan equine encephalitis viruses
68. Infection and activation of monocytes by Marburg and Ebola viruses
69. A system for functional analysis of Ebola virus glycoprotein
70. Vesicular release of Ebola virus matrix protein VP40
71. Recruiting the 2-5A system for antisense therapeutics
72. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection
73. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases
74. Processing of the Ebola virus glycoprotein by the proprotein convertase furin
75. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity
76. Functional importance of the coiled-coil of the Ebola virus glycoprotein
77. Epitopes involved in antibody-mediated protection from Ebola virus
78. Ebola virus: The search for vaccines and treatments
79. Characterization of Ebola virus entry by using pseudotyped viruses: Identification of receptor-deficient cell lines